About Circular Genomics
Circular Genomics is a company based in Albuquerque (United States) founded in 2021 by Nikolaos Mellios. Circular Genomics has raised $45.59 million across 7 funding rounds from investors including The University of New Mexico, Alzheimer's Drug Discovery and Mountain Group Partners. The company has 1 employees as of July 01, 2024. Circular Genomics offers products and services including MindLight. Circular Genomics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Albuquerque, United States
- Employees 1 as on 01 Jul, 2024
- Founders Nikolaos Mellios
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Circular Genomics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$45.59 M (USD)
in 7 rounds
-
Latest Funding Round
$15 M (USD), Series A
Dec 01, 2025
-
Investors
The University of New Mexico
& 5 more
-
Employee Count
1
as on Jul 01, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Circular Genomics
Circular Genomics offers a comprehensive portfolio of products and services, including MindLight.
Predicts patient response to antidepressants using circular RNA biomarkers.
People of Circular Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Circular Genomics
Circular Genomics has successfully raised a total of $45.59M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $15 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Circular Genomics
Circular Genomics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The University of New Mexico, Alzheimer's Drug Discovery and Mountain Group Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is directed toward life sciences and technology sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are focused on life sciences companies.
|
Locked | Locked | Locked |
Investor details for Circular Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Circular Genomics
Investment portfolio details for Circular Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Circular Genomics
Detailed financials for Circular Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Circular Genomics Comparisons
Peer comparison for Circular Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Circular Genomics
Circular Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Circular Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Circular Genomics
Complete news archive for Circular Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Circular Genomics
Circular Genomics was founded in 2021.
Circular Genomics is headquartered in Albuquerque, United States. It is registered at Albuquerque, New Mexico, United States.
Circular Genomics is a funded company, having raised a total of $45.59M across 7 funding rounds to date.
As of Jul 01, 2024, the latest employee count at Circular Genomics is 1.
Circular Genomics was founded in 2021 in Albuquerque, United States, within the biotechnology sector focused on genomics. RNA-based diagnostics and therapeutics are offered to address depression and related psychiatric conditions. A circular RNA-based genomic assay has been developed as a biomarker to predict therapeutic responses in individuals with neurological disorders. Operations center on advancing these tools for clinical applications.
Circular Genomics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Circular Genomics offers MindLight.
Circular Genomics has 6 investors. Key investors include The University of New Mexico, Alzheimer's Drug Discovery, Mountain Group Partners, Cottonwood Technology Fund, and Tramway Ventures.